You are here

TESARO Announces Participation at Two Investor Conferences

WALTHAM, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:       

  • The Cantor Global Healthcare Conference at the InterContinental New York Barclay Hotel on Wednesday, October 3, 2018. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to present an overview of the Company’s business and development programs at 11:30 AM ET and will also host meetings with investors.
  • The Leerink Partners Roundtable Series: Rare Disease & Oncology at the Lotte New York Palace on Wednesday, October 3, 2018. Mary Lynne Hedley, Ph.D., President and COO of TESARO, and Timothy Pearson, Executive Vice President and CFO of TESARO, will participate in an analyst-led fireside chat at 1:30 PM ET and will also host meetings with investors.

Live webcasts of the presentations at the Cantor and Leerink Partners conferences will be available by visiting the Investors section of the TESARO website at Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.

TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people facing cancer. For more information, visit, and follow us on Twitter and LinkedIn.

For additional information, please contact:
Kate Rausch

Wednesday, September 19, 2018 - 16:15

More Headlines

Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection
Hope For Patients With Highly Aggressive Form of AML
Oncology Therapy for Adult and Pediatric Tumors With a Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene Fusion
First Hedgehog Pathway Inhibitor Approved for AML in Adults Aged 75 and Older
Gene Therapy Granted Regenerative Medicine, Fast Track Designations